electroCore, Inc.

ECOR

US28531P2020

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Other stock markets 11:33:52 2024-04-25 am EDT			5-day change	1st Jan Change
5.58 ^USD	-0.00%		-1.07%	-6.25%

Apr. 08	ElectroCore, Inc. Announces the Launch of Truvaga Plus® for General Wellness	CI
Mar. 13	ElectroCore, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

ElectroCore, Inc. Provides Preliminary Unaudited Earnings Guidance for the Third Quarter of 2021

October 12, 2021 at 08:00 am EDT

electroCore, Inc. provided preliminary unaudited earnings guidance for the third quarter of 2021. For the quarter, the company expects revenue will be approximately $1.5 million.

Latest news about electroCore, Inc.

ElectroCore, Inc. Announces the Launch of Truvaga Plus® for General Wellness	Apr. 08	CI
ElectroCore, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Transcript : ElectroCore, Inc., Q4 2023 Earnings Call, Mar 13, 2024	Mar. 13
ElectroCore, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
Earnings Flash (ECOR) ELECTROCORE Posts Q4 Revenue $5.2M, vs. Street Est of $5M	Mar. 13	MT
Certain Common Stock of electroCore, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2024.	Jan. 27	CI
Certain Warrants of electroCore, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2024.	Jan. 27	CI
Certain Options of electroCore, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2024.	Jan. 27	CI
HC Wainwright Adjusts electroCore Price Target to $15 From $11, Maintains Buy Rating	Jan. 22	MT
Ondine Biomedical appoints Joseph Errico as new CFO	Jan. 16	AN
ElectroCore Says Two US Patents Issued for Non-Invasive Vagus Nerve Stimulation Technology	Dec. 26	MT
ElectroCore, Inc. Appoints Charles S. Theofilos as New Class Iii Member of the Board	Dec. 14	CI
Transcript : ElectroCore, Inc. - Analyst/Investor Day	Nov. 21
HC Wainwright Adjusts Price Target on electroCore to $11 From $10, Maintains Buy Rating	Nov. 09	MT
Transcript : ElectroCore, Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
ElectroCore, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Earnings Flash (ECOR) ELECTROCORE Posts Q3 Revenue $4.5M, vs. Street Est of $3.8M	Nov. 08	MT
Electrocore, Inc. Announces Data Highlighting Non-Invasive Vagus Nerve Stimulation for Treatment of Symptoms of Gastroparesis	23-10-24	CI
ElectroCore, Inc. Announces Two-Year Extension of Gammacore Device Listing in the NHS Supply Chain Catalogue	23-10-17	CI
ElectroCore, Inc. Announces the Publication of Two Peer Reviewed Publication of Two Peer Reviewed Publications Supporting the Use of Gammacore ( Non-Invasive Vagus Nerve Stimulation; nVNS) in Patients with Post Traumatic Stress Disorder	23-09-27	CI
ElectroCore Wins Dismissal of Lawsuit Over 2018 Initial Public Offering	23-08-23	MT
Transcript : ElectroCore, Inc., Q2 2023 Earnings Call, Aug 09, 2023	23-08-09
ElectroCore, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Earnings Flash (ECOR) ELECTROCORE Reports Q2 Revenue $3.6M, vs. Street Est of $3.5M	23-08-09	MT
ElectroCore, Inc. Reiterates Revenue Guidance for the Year 2023	23-08-09	CI

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company. It provides non-invasive vagus nerve stimulation (nVNS) technology platform. The Companyâs product categories include Handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and Handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire, is a prescription medical device that is used for a variety of primary headache conditions. Its Truvaga is a personal use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. The Companyâs TAC-STIM product is not a medical device and is not intended to diagnose, cure, mitigate, prevent, or treat a disease or condition.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for electroCore, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.58 USD

Average target price

23.1 USD

Spread / Average Target

+313.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Equipment

	1st Jan change	Capi.
ELECTROCORE, INC.	-6.25%	33.49M
SHOCKWAVE MEDICAL, INC.	+72.69%	12.34B
PENUMBRA, INC.	-19.01%	7.98B
MASIMO CORPORATION	+14.00%	7.19B
GETINGE AB	+2.18%	5.81B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+6.51%	5.04B
APT MEDICAL INC.	+21.99%	4.31B
ASAHI INTECC CO., LTD.	-20.27%	4.03B
INARI MEDICAL, INC.	-41.43%	2.21B
SKAN GROUP AG	+0.87%	1.99B

Medical Equipment

electroCore, Inc.

Equities

ECOR

US28531P2020

Medical Equipment, Supplies & Distribution

ElectroCore, Inc. Provides Preliminary Unaudited Earnings Guidance for the Third Quarter of 2021

Latest news about electroCore, Inc.

Chart electroCore, Inc.

Company Profile

Income Statement Evolution

Ratings for electroCore, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Medical Equipment